瑞银发表报告,列出最具潜力超市场预期收益((Buy rated HK listed stocks with highest UBSe earnings upside above consensus estimate)的港股买入名单:股份│瑞银与同业对企业今明两年综合盈测差异康希诺生物(06185.HK) +0.690 (+1.577%) 沽空 $2.39百万; 比率 7.839% │97%石药集团(01093.HK) -0.120 (-1.213%) 沽空 $1.83亿; 比率 26.455% │60%三生制药(01530.HK) +0.560 (+1.854%) 沽空 $5.28千万; 比率 8.989% │42%科济药业-B(02171.HK) +0.620 (+3.166%) 沽空 $3.72百万; 比率 10.451% │42%上石化(00338.HK) +0.010 (+0.752%) 沽空 $53.06万; 比率 12.999% │37%越秀地产(00123.HK) +0.020 (+0.440%) 沽空 $4.04百万; 比率 22.441% │35%金风科技(02208.HK) -0.010 (-0.139%) 沽空 $73.48万; 比率 4.319% │33%科伦博泰生物-B(06990.HK) +3.200 (+0.790%) 沽空 $1.44千万; 比率 9.972% │27%中信建投证券(06066.HK) +0.170 (+1.375%) 沽空 $5.40百万; 比率 9.985% │26%恒瑞医药(01276.HK) +4.200 (+5.593%) │25%海丰国际(01308.HK) -0.190 (-0.738%) 沽空 $3.32百万; 比率 18.852% │23%药明康德(02359.HK) -1.100 (-1.082%) 沽空 $2.02亿; 比率 34.991% │22%(wl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-04 12:25。)